Bora Pharmaceuticals acquires Eden Biologics CDMO
Bora establishes a leadership position in Taiwan's CDMO sector as it continues to expand into the global CDMO market
Source: ryt9.com
Stay updated with breaking news from Eden Biologic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Bora establishes a leadership position in Taiwan's CDMO sector as it continues to expand into the global CDMO market
Eden Biologics today announced completion of enrollment for Phase 1 PK Clinical Trial of Eden's lead product candidate EB1001, a Denosumab biosimilar.